Mengying Cao

Mengying Cao

Auto-generated profile, based on publicly available information

Mengying Cao

Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital and Institutes of Biomedical Sciences (P.G., M.C., X.W., H.Z., Lin Li, C.Y., J.Y., J.G., Liliang Li, Y.Z.), Fudan University, Shanghai, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2023 in Circulation
Verified
Journal Article
Closed access
PDF file
YZYunzeng Zou
Yunzeng Zou
MCMengying Cao
Mengying Cao
XJXueli Jiang
Xueli Jiang
XWXiaolin Wang
Xiaolin Wang
GZGuoping Zhang
Guoping Zhang
YZYunzeng Zou
Yunzeng Zou
Background: Diabetic heart dysfunction is a common complication of diabetes. Cell death is a core event that leads to diabetic heart dysfunction. However, the time sequence of cell death pathways and the precise time to intervene of particular cell death type remain largely unknown in the diabetic heart. This study aims to identify the particular cell death type that is responsible for diabetic heart dysfunction and to propose a promising therapeutic strategy by intervening in the cell death pathway. Methods: Type 2 diabetes models were established using db/db leptin receptor–deficient mice and high-fat diet/streptozotocin–induced mice. The type 1 diabetes model was established in streptozotocin-induced mice. Apoptosis and programmed cell necrosis (necroptosis) were detected in diabetic mouse hearts at different ages. G protein–coupled receptor–targeted drug library was searched to identify potential receptors regulating the key cell death pathway. Pharmacological and genetic approaches that modulate the expression of targets were used. Stable cell lines and a homemade phosphorylation antibody were prepared to conduct mechanistic studies. Results: Necroptosis was activated after apoptosis at later stages of diabetes and was functionally responsible for cardiac dysfunction. Cannabinoid receptor 2 (CB2R) was a key regulator of necroptosis. Mechanically, during normal glucose levels, CB2R inhibited S6 kinase–mediated phosphorylation of BACH2 at serine 520, thereby leading to BACH2 translocation to the nucleus, where BACH2 transcriptionally repressed the necroptosis genes Rip1 , Rip3 , and Mlkl . Under hyperglycemic conditions, high glucose induced CB2R internalization in a β-arrestin 2–dependent manner; thereafter, MLKL (mixed lineage kinase domain-like), but not receptor-interacting protein kinase 1 or 3, phosphorylated CB2R at serine 352 and promoted CB2R degradation by ubiquitin modification. Cardiac re-expression of CB2R rescued diabetes-induced cardiomyocyte necroptosis and heart dysfunction, whereas cardiac knockout of Bach2 diminished CB2R-mediated beneficial effects. In human diabetic hearts, both CB2R and BACH2 were negatively associated with diabetes-induced myocardial injuries. Conclusions: CB2R transcriptionally repressed necroptosis through interaction with BACH2; in turn, MLKL formed a negative feedback to phosphorylate CB2R. Our study provides the integrative view of a novel molecular mechanism loop for regulation of necroptosis centered by CB2R, which represents a promising alternative strategy for controlling diabetic heart dysfunction.

23 September 2025 in Circulation
Verified
Journal Article
Closed access
YZYunzeng Zou
Yunzeng Zou
MCMengying Cao
Mengying Cao
XWXiaolin Wang
Xiaolin Wang
HZHongyuan Zhang
Hongyuan Zhang
XCXuanlong Chen
Xuanlong Chen
YZYunzeng Zou
Yunzeng Zou
BACKGROUND: GRKs (GPCR [G protein–coupled receptor] kinases) are key regulators of GPCR signaling. Because GPCRs are targeted by approximately 40% of clinical drugs, GRKs also represent therapeutic targets for combating cardiovascular diseases. However, the predominant GRK that responds to diabetic heart injury and the underlying mechanisms remain largely unknown. METHODS: Human and mouse diabetic heart tissues were used to assess the expression pattern of the predominant GRK. Cardiac conditional knockout mice, heart-restricted adeno-associated virus 9, CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 (CRISPR-associated protein 9)-mediated gene editing, and pharmacological modulators were used for functional investigation. Heart histopathology and function were evaluated by hematoxylin-eosin staining, wheat germ agglutinin staining, Sirius red staining, Masson trichrome staining, and echocardiography. Immunoprecipitation, electrophoretic mobility shift assays, site-specific mutation, autodocking, and molecular dynamics simulation were conducted for mechanism studies. Computer-aided virtual screening was conducted to identify inhibitors of the predominant GRK. RESULTS: GRK3 was the predominant GRK that was significantly upregulated in cardiomyocytes from both human and mouse diabetic hearts. Expression of GRK3 positively correlated with cardiac fibrosis and hypertrophy in human diabetic hearts. Heart-restricted overexpression of GRK3 aggravated, whereas conditional knockout of GRK3 in cardiomyocytes significantly relieved, heart injuries elicited by hyperglycemia. Mechanistically, hyperglycemia upregulated GRK3 expression by inhibiting the transcriptional repressor YY1 (Yin-Yang 1). GRK3 then essentially targeted CB2R (cannabinoid receptor 2) to phosphorylate CB2R at serine 335 (S335) and promote β-arrestin 2–mediated internalization and ubiquitin-dependent degradation of CB2R. Modulation of either YY1 or CB2R perturbed GRK3 functions in the diabetic hearts. Virtual screening identified a small molecule, isochlorogenic acid A, as an efficient GRK3 inhibitor that protects the heart from diabetic injury without causing additional side effects. CONCLUSIONS: GRK3 is the predominant GRK that aggravates diabetic heart injury. YY1-dependent upregulation of GRK3 functions through direct phosphorylation of CB2R. Small molecules targeting GRK3 may represent a promising avenue for curing diabetic heart injury in the clinic.

Verified
Journal Article
Open access
PDF file
XWXiaolin Wang
Xiaolin Wang
MCMengying Cao
Mengying Cao
ZLZILONG LIU
ZILONG LIU
LCLiming Chen
Liming Chen
YZYufei Zhou
Yufei Zhou
YZYunzeng Zou
Yunzeng Zou
Cardiovascular disease is an essential comorbidity in patients with non-small cell lung cancer (NSCLC) and represents an independent risk factor for increased mortality. Therefore, careful monitoring of cardiovascular disease is crucial in the healthcare of NSCLC patients. Inflammatory factors have previously been associated with myocardial damage in NSCLC patients, but it remains unclear whether serum inflammatory factors can be utilized to assess the cardiovascular health status in NSCLC patients. A total of 118 NSCLC patients were enrolled in this cross-sectional study, and their baseline data were collected through a hospital electronic medical record system. Enzyme-linked immunosorbent assay (ELISA) was used to measure the serum levels of leukemia inhibitory factor (LIF), interleukin (IL)-18, IL-1β, transforming growth factor-β1 (TGF-β1), and connective tissue growth factor (CTGF). Statistical analysis was performed using the SPSS software. Multivariate and ordinal logistic regression models were constructed. The data revealed an increased serum level of LIF in the group using tyrosine kinase inhibitor (TKI)-targeted drugs compared to non-users (p < 0.001). Furthermore, serum TGF-β1 (area under the curve, AUC: 0.616) and cardiac troponin T (cTnT) (AUC: 0.720) levels were clinically evaluated and found to be correlated with pre-clinical cardiovascular injury in NSCLC patients. Notably, the serum levels of cTnT and TGF-β1 were found to indicate the extent of pre-clinical cardiovascular injury in NSCLC patients. In conclusion, the results suggest that serum LIF, as well as TGFβ1 together with cTnT, are potential serum biomarkers for the assessment of cardiovascular status in NSCLC patients. These findings offer novel insights into the assessment of cardiovascular health and underscore the importance of monitoring cardiovascular health in the management of NSCLC patients.